Papers/PMID:32969022
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Acta neurologica Scandinavica2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
cannabidiol — increases seizure frequency 50% responder rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“In the overall DS population, CBD resulted in a greater reduction in convulsive seizures (0.71 [0.60‐0.83], p < 0.0001) and higher ≥50% responder rates (2.34 [1.51‐3.63], p = 0.0001) compared with placebo.”
Quoted verbatim from Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 18 years with Dravet syndrome in two pooled phase 3 trials (GWPCARE1B and GWPCARE2), all CBD doses (10 and 20 mg/kg/day) versus placebo, overall population; concomitant antiepileptic drugs in both arms
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.2021PMID:32969022Industry fundedPermalink